Skip to main content
OpenTrials
Completed

NCT Number: NCT01303757

A Novel Diet-Phenotype Interaction Affecting Body Weight

The primary aim of the study is to examine insulin secretion as an effect modifier of the efficacy of a low-fat vs. low-glycemic load diet for weight loss among overweight/obese young adults in an 18-month, prospectively stratified, multi-center randomized controlled trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Hospital Boston, Boston, Massachusetts, United States

Loading trial locations.

About this study

In recent years, diets of widely varying composition have been used in the treatment of obesity. While none of these diets has produced consistent, long-term weight loss, some individuals on virtually all types of diets do remarkably well. One explanation for this variation among individuals is differences in motivation and behavior. However, underlying biological differences may also play an important role. Previous work has identified insulin secretion (as quantified by serum insulin concentration at 30 minutes following a standard 75-gram oral glucose load) as an important biological determinant. This randomized-controlled, multi-center trial aims to test the hypothesis that insulin secretion will predict which type of diet will work best for each individual. A total of 160 obese young adults (18 to 40 years) will be assigned to one of two diets: low-fat (60% carbohydrate, 20% fat, 20% protein) or low-glycemic load (45% carbohydrate, 35% fat, 20% protein). Participants will be enrolled at two sites (Children's Hospital Boston or University of North Carolina-Chapel Hill) and assigned to diet groups according to baseline insulin secretion status. The protocol will include an intensive 6-month intervention period and a 12-month follow-up period. Registered dietitians will provide nutrition education and behavioral counseling during group workshops and scheduled telephone calls. In an effort to avoid confounding, close attention will be paid to control for treatment intensity, physical activity prescriptions, and behavioral methods between groups. The primary endpoint will be percent body fat by DXA scan. Secondary endpoints will include cardiovascular and diabetes risk factors. Repeated, 24-hour dietary and physical activity recall interviews will provide process data. Metabolomic profiling and molecular analysis of identified metabolites will be conducted to characterize phenotype and explore potential physiological mechanisms. A successful outcome of this work will inform the practice of "personalized" nutritional therapy, enhancing the ability to select the most efficacious weight loss diet for an individual based on underlying biological differences.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 to 40 years.
  • Body mass index (BMI) ≥ 27 kg/m2.
  • Body weight ≤ 300 lb.
  • Access to a working telephone.
  • Clearance in writing from a primary care provider (i.e., physician or nurse practitioner) to rule out pre-existing medical conditions.
  • Willing and able to attend group workshops (for dietary intervention) on specified evenings.

Exclusion criteria

  • Physician diagnosis of a major medical illness or eating disorder.
  • Chronic use of any medication that may affect study outcomes (e.g., insulin-sensitizing agents).
  • Current smoking (i.e., 1 cigarette in the past week).
  • Physical, mental, or cognitive handicaps that prevent participation.
  • Another member of the family (i.e., first degree relative) or household participating in the study.
  • Planning to relocate from current area of residence during the proposed timeframe for study participation.
  • If female, planning to become pregnant during the 18 months of the study.

Treatment and study plan

Dietary counselling

Behavioral

Primary outcomes

  1. Percent body fat by dual-energy x-ray absorptiometry (DXA)

    Time frame: 18 months

Secondary outcomes

  1. Triglyceride

    Time frame: 18 months

  2. HDL cholesterol

    Time frame: 18 months

  3. LDL cholesterol

    Time frame: 18 months

  4. C-reactive protein

    Time frame: 18 months

  5. Plasminogen Activator Inhibitor-1

    Time frame: 18 months

  6. Fasting blood glucose

    Time frame: 18 months

  7. Insulin resistance

    Time frame: 18 months

  8. Blood pressure

    Time frame: 18 months

  9. Trunk fat

    Time frame: 18 months

Other outcomes

  1. Serum insulin concentration 30 minutes following a standard 75-gram oral glucose load

    Time frame: 18 months

    Effect modification

  2. Metabolomic profile

    Time frame: 18 months

    Effect modification

  3. Insulin sensitivity

    Time frame: 18 months

    Effect modification

  4. Abdominal-to-total fat ratio

    Time frame: 18 months

    Effect modification

  5. Waist-to-hip ratio

    Time frame: 18 months

    Effect modification

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Broad Institute of MIT and Harvard
  • University of North Carolina, Chapel Hill

Registry information

Acronym: FRESH Start

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Feb 25, 2011
Registry last updated
Feb 9, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.